文献速递产科母胎医学

宫颈成熟球囊与口服米索前列醇用于小于胎龄儿引产的比较:回顾性多中心研究

Cervical ripening balloon vs oral misoprostol for induction of labor in small-for-gestational age: retrospective multicenter study.
PubMed 文献 · Ultrasound Obstet Gynecol · 2025-11-26

这项回顾性多中心队列研究纳入848例估计胎儿体重小于第10百分位且Bishop评分小于7分的单胎妊娠,于孕37周后引产,比较仅用宫颈成熟球囊与口服米索前列醇(可联合球囊)的母儿结局。经逆概率加权调整后,两组剖宫产率无显著差异(aOR 1.29,95%CI 0.82-2.04),米索前列醇组手术阴道分娩和缩宫素加强的需求更低。作者认为口服米索前列醇是此类高危人群安全有效的引产选择,但需随机对照试验证实。

要点

  • 调整后两组剖宫产率无显著差异(aOR 1.29,95%CI 0.82-2.04)。
  • 米索前列醇组手术阴道分娩(aOR 0.33)和缩宫素加强(aOR 0.04)需求更低。
  • 米索前列醇组子宫过度刺激更常见,但未增加胎儿窘迫剖宫产或不良新生儿结局。

核心结论

  • 在晚发型胎儿生长受限或小于胎龄儿妊娠中,口服米索前列醇与仅机械性宫颈成熟相比未增加剖宫产风险,并与手术干预和引产加强需求减少相关。
  • 作者认为这些发现支持口服米索前列醇作为该高危人群引产的安全有效选择。
  • 作者指出需随机对照试验证实这些结果。

研究设计与样本

  • 回顾性多中心队列研究,纳入三个欧洲三级中心单胎妊娠、估计胎儿体重小于第10百分位且Bishop评分小于7分、孕37周后因疑似小于胎龄儿或晚发型胎儿生长受限引产的孕妇。
  • 共848例纳入分析,431例(50.8%)仅接受宫颈成熟球囊,417例(49.2%)接受口服米索前列醇联合或不联合宫颈成熟球囊。
  • 排除既往剖宫产、接受阴道米索前列醇、早发型胎儿生长受限、胎儿结构异常或阴道分娩禁忌者。
  • 采用逆概率治疗加权处理基线差异,并使用双重稳健估计调整混杂因素。

主要发现

  • 调整后两组剖宫产率无显著差异(aOR 1.29,95%CI 0.82-2.04)。
  • 米索前列醇组较仅球囊组手术阴道分娩更少(aOR 0.33,95%CI 0.18-0.64),需缩宫素加强更少(aOR 0.04,95%CI 0.03-0.07)。
  • 米索前列醇组引产开始后24小时内自然阴道分娩也更少(aOR 0.49,95%CI 0.33-0.74)。
  • 米索前列醇联合或不联合球囊组子宫过度刺激更常见,但未与因胎儿窘迫剖宫产率升高或不良新生儿结局相关。
  • 两组新生儿重症监护病房入住率相似;确诊晚发型胎儿生长受限的亚组分析结果相当。

临床怎么用

  • 作者认为口服米索前列醇可作为晚发型胎儿生长受限或小于胎龄儿妊娠引产的安全有效选择。
  • 作者指出需随机对照试验证实这些结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the maternal and neonatal outcomes following induction of labor (IOL) using oral misoprostol vs mechanical cervical ripening using a cervical ripening balloon (CRB) in singleton pregnancies complicated by small-for-gestational age (SGA), including those with late-onset fetal growth restriction (FGR). METHODS: This was a retrospective multicenter cohort study of women with a singleton pregnancy with estimated fetal weight < 10th percentile and a Bishop score of < 7, who underwent IOL ≥ 37 weeks' gestation for suspected SGA or late-onset FGR in one of three European tertiary centers. Participants were assigned to one of two groups depending on whether they underwent cervical ripening using a CRB without pharmacologic agents (CRB-only group) or received oral misoprostol with or without a CRB (misoprostol group). Women who had had a prior Cesarean delivery (CD), those who received vaginal misoprostol and those with early-onset FGR, fetal structural anomalies or contraindications to vaginal delivery were excluded. The primary outcome was CD. Secondary outcomes included spontaneous vaginal delivery (SVD) within 24 h after starting IOL, operative vaginal delivery (OVD), oxytocin augmentation, uterine tachysystole and neonatal outcomes. Inverse probability of treatment weighting was used to account for baseline differences and doubly robust estimation was used to adjust for confounders. RESULTS: A total of 848 women was included in the analysis, of whom 431 (50.8%) received a CRB only and 417 (49.2%) received oral misoprostol with or without a CRB. Baseline characteristics differed between the two groups, with women in the misoprostol group being older, more often nulliparous and undergoing IOL later in gestation. After adjustment, there was no significant difference in the rate of CD between the two groups (adjusted odds ratio (aOR), 1.29 (95% CI, 0.82-2.04)). Women receiving misoprostol were significantly less likely to undergo OVD (aOR, 0.33 (95% CI, 0.18-0.64)) or require oxytocin augmentation (aOR, 0.04 (95% CI, 0.03-0.07)) compared with the CRB-only group. SVD within 24 h after starting IOL was also less likely in the misoprostol group (aOR, 0.49 (95% CI, 0.33-0.74)). Uterine tachysystole occurred more frequently in the misoprostol ± CRB group, but this was not associated with higher rates of CD for fetal distress or adverse neonatal outcomes. The rate of admission to the neonatal intensive care unit was similar between the two groups. Subgroup analysis in pregnancies with confirmed late-onset FGR yielded comparable findings. CONCLUSIONS: In pregnancies complicated by late-onset FGR or SGA, oral misoprostol did not increase the risk of CD compared with mechanical cervical ripening only, and was associated with a reduced need for operative interventions and labor augmentation. These findings support the use of oral misoprostol as a safe and effective option for IOL in this high-risk population. Randomized controlled trials are needed to confirm these results. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Zaccaria G, Dutemeyer V, Carlin A, et al. Cervical ripening balloon vs oral misoprostol for induction of labor in small-for-gestational age: retrospective multicenter study. Ultrasound Obstet Gynecol. 2025. PMID: 41305845. doi:10.1002/uog.70142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。